🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Learn more: novocure.com/novocure-to-re… $NVCR

Glioblastoma (GBM) Awareness Day is coming up. On #GBMDay and every day, we recognize the impact of GBM, the most common primary brain cancer, on patients and caregivers. Read just a few of their stories: novocure.com/patient-experi…

We reported financial results for the quarter ended June 30, 2024, including quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, up 11% compared to the same period in 2023. novocure.com/novocure-repor… #earnings #NVCR

This #WorldLungCancerDay, we thank the doctors, nurses, caregivers, patient organizations and all who support patients facing this difficult disease. #lungcancer

Novocure will participate in the 2024 Wells Fargo Healthcare Conference on September 4. William Doyle, our Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors. Listen live on Sep 4 here: novocure.com/investor-relat…

FDA approves Novocure’s treatment for metastatic non-small cell lung cancer (mNSCLC) for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with mNSCLC who progressed on or after a platinum-based regimen: novocure.com/fda-approves-n…

Novocure reports Q3 financial results and announces the appointment of Christoph Brackmann as CFO, effective January 1, 2025. For more information, see our press releases: novocure.com/press-releases/

Novocure has announced positive topline results from Phase 3 PANOVA-3 clinical trial of Tumor Treating Fields (TTFields) Therapy in unresectable locally advanced pancreatic cancer. Read the press release here: novocure.com/novocure-annou…

Today, Novocure announced its financial results for the quarter and full year that ended December 31, 2024. For more information, read the press release: novocure.com/novocure-repor…

Novocure announced today that management will participate in the Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11, 2025. For more information, read the press release: novocure.com/novocure-parti…

Novocure will report financial results for the first quarter 2025 on April 24, 2025, before the U.S. financial markets open, as well as host a conference call and webcast to discuss the financial results. Read the press release for more information: novocure.com/novocure-repor…

Novocure has received a CE Mark for its metastatic non-small cell lung cancer treatment, for use concurrently with immune checkpoint inhibitors or docetaxel, for adult patients who have progressed on or after a platinum-based regimen. See the press release novocure.com/novocures-optu…

Novocure today reported financial results for the first quarter ended March 31, 2025. Read the press release: novocure.com/novocure-repor…

Today, Novocure announced two upcoming investor events. Read more in our press release: novocure.com/novocure-annou…

Results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for #PancreaticCancer will be presented today at #ASCO25 and simultaneously published in theJournal of Clinical Oncology. ascopubs.org/doi/10.1200/JC… Read our press release: novocure.com/results-phase-…

Novocure will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open. Read more in our press release: novocure.com/novocure-repor…

Novocure will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields therapy for unresectable, locally advanced pancreatic cancer at the European Society for Medical Oncology (ESMO) GI Congress 2025. novocure.com/novocure-prese…